{
    "Clinical Trial ID": "NCT00867217",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Placebo",
        "  Placebo (3 capsules of matching placebo) along with standard of care medication (Standard Dose Vitamin D3; 600 IU of vitamin D3 daily) given weekly for 24 weeks",
        "INTERVENTION 2: ",
        "  Vitamin D",
        "  High Dose Vitamin D3 (3 capsules of 10,000 IU) capsules along with standard of care medication standard of care medication (Standard Dose Vitamin D3; 600 IU of vitamin D3 daily) given weekly for 24 weeks"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Post-menopausal women newly diagnosed with early stage breast cancer, who would be treated with an aromatase inhibitor",
        "  Serum 25OHD levels < 40 ng/ml",
        "Exclusion Criteria:",
        "  Severe or debilitating musculoskeletal pain",
        "  Known metastatic disease",
        "  History of renal stones",
        "  History of hypercalcemia or hyperthyroidism",
        "  Currently receiving adjuvant or neoadjuvant chemotherapy",
        "  Currently receiving other investigational agents"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Number of Participants With Worsening of Musculoskeletal Symptoms (MS)",
        "  Worsening of Musculoskeletal Symptoms (MS) is defined as any one of the following three events: (a) an increase by at least 0.25 in the Health Assessment Questionnaire II (HAQ II, a measure of disability from joint pain) score, (b) an increase in patient reported severity of joint and/or muscle pain, or (c) discontinuation from trial prior to 24 weeks specifically because of problems with musculoskeletal symptoms.",
        "  Time frame: Change from Baseline to 24 Weeks",
        "Results 1: ",
        "  Arm/Group Title: Placebo",
        "  Arm/Group Description: Placebo (3 capsules of matching placebo) along with standard of care medication (Standard Dose Vitamin D3; 600 IU of vitamin D3 daily) given weekly for 24 weeks",
        "  Overall Number of Participants Analyzed: 77",
        "  Measure Type: Number",
        "  Unit of Measure: participants  HAQ II increase by 0.25: 23",
        "  Subjective Pain increase: 24",
        "  Discontinuation due to AEs: 3",
        "  Any of the three measures: 39",
        "Results 2: ",
        "  Arm/Group Title: Vitamin D",
        "  Arm/Group Description: High Dose Vitamin D3 (3 capsules of 10,000 IU) capsules along with standard of care medication standard of care medication (Standard Dose Vitamin D3; 600 IU of vitamin D3 daily) given weekly for 24 weeks",
        "  Overall Number of Participants Analyzed: 70",
        "  Measure Type: Number",
        "  Unit of Measure: participants  HAQ II increase by 0.25: 18",
        "  Subjective Pain increase: 18",
        "  Discontinuation due to AEs: 0",
        "  Any of the three measures: 26"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 3/80 (3.75%)",
        "  Hemolysis * 1/80 (1.25%)",
        "  Cardiac Changes * 0/80 (0.00%)",
        "  Supraventricular arryhthmia * 0/80 (0.00%)",
        "  Colitis * 1/80 (1.25%)",
        "  CNS Ischemia * 1/80 (1.25%)",
        "  Wound Complications * 0/80 (0.00%)",
        "Adverse Events 2:",
        "  Total: 3/80 (3.75%)",
        "  Hemolysis * 0/80 (0.00%)",
        "  Cardiac Changes * 1/80 (1.25%)",
        "  Supraventricular arryhthmia * 1/80 (1.25%)",
        "  Colitis * 0/80 (0.00%)",
        "  CNS Ischemia * 0/80 (0.00%)",
        "  Wound Complications * 1/80 (1.25%)"
    ]
}